AstraZeneca's Saphnelo Shows Strong Uptake in Lupus Treatment, Driving Growth Story and Valuation Gap

AstraZeneca's Saphnelo is seeing rapid uptake in cutaneous lupus erythematosus prescribing, surpassing GSK's Benlysta for biologic management. This supports the company's immunology push and autoimmune franchise. Upcoming pivotal trials for Saphnelo are a notable area of interest, influencing capital allocation and the broader immunology pipeline. The share price is trading 14% below analyst target and 41.2% below estimated fair value. Key considerations include rapid Saphnelo uptake, upcoming trial readouts, and high debt levels.